Speaker(s): 

Shriraj S. Patel, DO, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Michaelyn Notz, DO, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• discuss the rationale behind the name change and how it reflects a deeper understanding of disease pathophysiology
• recognize the rising prevalence, serious long-term consequences, and underappreciated impact of MASLD on global health
• identify how MASLD intersects with other specialties and why early recognition matters in diverse clinical settings

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Michaelyn Notz, DO; Jeff Summers, DO and Kamran Namjouyan, DO have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None